LSD is the second substance people actually microdose, and it is chemically nothing like the first. It is an ergoline — derived from ergot alkaloids — whereas psilocybin is a tryptamine; they meet only at the receptor, both acting as 5-HT2A agonists. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 LSD is active in micrograms and long-lasting, with a plasma course characterised in controlled human study. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 Its place in microdosing research is anchored by a self-blinding citizen-science study, which is best read as a demonstration of how powerful expectancy is rather than as evidence that microdosing beats placebo. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 As with every substance here, what LSD is is far better characterised than what a microdose of it does, [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 and this page describes the compound without recommending or dosing it.
This is an education-only research review, not sourcing, dosing, medical, or legal advice. It describes LSD as a compound and what its research examines. It is not a guide to obtaining, dosing, or scheduling anything, and it offers no safe-or-unsafe verdict. Dosing belongs to protocols, risk to safety, and legality is covered separately. For personal decisions, consult a qualified clinician.
What LSD is
Lysergic acid diethylamide is a semi-synthetic ergoline: its core is lysergic acid, an ergot alkaloid, modified with a diethylamide group. This places it in a different chemical family from the tryptamine psychedelics such as psilocybin and DMT. The shared feature that makes it a “classic” psychedelic is pharmacological, not structural — agonist activity at the serotonin 5-HT2A receptor. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 Two descriptive features set LSD apart from psilocybin: it is active at microgram quantities, and at perceptual doses it lasts far longer.
| LSD | Psilocybin | |
|---|---|---|
| Chemical family | Ergoline | Tryptamine |
| Active quantity | Micrograms | Milligrams (of compound) |
| Perceptual duration | ~8–12 hours | ~4–6 hours |
| Source | Synthetic | Mushroom-derived |
| Shared mechanism | 5-HT2A agonist | 5-HT2A agonist |
Pharmacokinetics and why precision is hard
Controlled human pharmacokinetic work has characterised LSD’s plasma concentration over time and its relationship to autonomic and subjective effects, confirming a long duration that tracks plasma levels. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 That long duration is not just a practical detail. It changes the window during which subtle, unexpected, or impairing effects could occur, lengthens any interaction window, and shapes how a person interprets faint effects over a whole day — which makes LSD less directly comparable to shorter-acting psilocybin. A longer-acting compound is not therefore worse or safer; it means the evidence and risk questions are simply different.
The same property that makes LSD remarkable — activity in micrograms — makes consistent dosing difficult outside a laboratory. In controlled research, LSD can be administered in defined microgram amounts; outside that context, nominal amounts may not reflect the actual delivered dose. Because the active quantity is so small, tiny absolute variation produces large proportional variation in dose, and illicit blotter or liquid is not made to pharmaceutical uniformity. The microdosing literature repeatedly flags dose standardisation as the central methodological problem. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 This is a description of why studies emphasise verification, not advice about how to dose; the practical question of “how much” belongs to protocols, and the difficulty of studying low doses to why microdosing is difficult to study.
Same class, different intervention
LSD and psilocybin are both classic serotonergic psychedelics, but their duration, potency scale, receptor-binding profile, and study designs differ. Evidence from one should be used to generate questions about the other, not to answer them automatically. Sharing the 5-HT2A target makes the two compounds related; it does not make a finding about psilocybin a finding about LSD, or the reverse. Compound-specific evidence is the standard, and a shared label is not shared evidence.
The self-blinding study
LSD anchors one of the most important pieces of microdosing methodology: a self-blinding citizen-science study in which participants prepared their own microdose and placebo capsules so they did not know which they were taking. Participants who microdosed reported psychological improvements — but so did those on placebo, and once expectancy was accounted for the differences between conditions largely vanished. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 The value of the study is not a verdict that LSD microdosing “works” or “fails”; it is a demonstration of how large the placebo and expectation component is, and of how a clever low-cost design can begin to separate the two.
| Claim you might hear | What the study supports |
|---|---|
| ”LSD microdosing improves mood” | People reported improvement — including on placebo |
| ”The study proved it works” | It showed expectancy explains much of the reported benefit |
| ”The study proved it fails” | It was not powered to rule out small real effects |
| ”Self-report settles it” | Reports are real but are not controlled outcomes |
Holding the distinctions
LSD illustrates the cluster’s anchor cleanly. Full-dose is not microdose: its pharmacokinetics and receptor pharmacology come from perceptual doses and do not establish what a microgram-scale dose does. Reports are not outcomes: the self-blinding work shows how readily self-reported benefit appears without a substance effect. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 And pharmacological similarity is not interchangeability: sharing a receptor target with psilocybin does not make the two substances equivalent for microdosing, given their different chemistry, potency scale, and duration. For how the shared mechanism works, see the 5-HT2A mechanism; for what the evidence can and cannot certify, the limits-of-evidence capstone in Safety.
- Ergoline, not tryptamine
- LSD is chemically unrelated to psilocybin; they share only the 5-HT2A target. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478
- Microgram activity
- LSD is active in micrograms and long-lasting, which makes dose precision the central research difficulty. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9
- Self-blinding lesson
- Expectancy explained much of the reported microdosing benefit in the self-blinding study. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878
- Similar ≠ interchangeable
- A shared receptor does not make LSD and psilocybin equivalent for microdosing.
Frequently asked questions
What kind of substance is LSD?
LSD — lysergic acid diethylamide — is a semi-synthetic ergoline, a chemical family derived from ergot alkaloids. That makes it chemically unrelated to psilocybin, which is a tryptamine, even though both act as agonists at the serotonin 5-HT2A receptor. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 LSD is notable for being active at very small (microgram) quantities and for a long duration of action, roughly eight to twelve hours at perceptual doses. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 This page describes what LSD is and what its research examines; it is not a guide to obtaining or dosing it.
Why is LSD harder to microdose precisely than psilocybin?
Because it is active in micrograms, very small absolute differences in the amount on a given unit translate into large proportional differences in dose, and illicit blotter is not manufactured to pharmaceutical uniformity. The literature treats dose standardisation as the central practical difficulty in LSD microdosing research. [4] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 None of this is sourcing or dosing guidance — it is a description of why studies emphasise dose verification and why claims about a fixed LSD microdose should be read cautiously.
What did the self-blinding LSD studies actually find?
A citizen-science self-blinding study had participants microdose or take placebo without knowing which, using an at-home blinding procedure. Participants reported psychological improvements, but the improvements occurred in the placebo group too, and the differences between microdose and placebo largely disappeared once expectation was accounted for. [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 The honest summary is that the study is a methodological landmark showing how strong expectancy effects are, not a demonstration that LSD microdosing produces benefits beyond placebo.
Does LSD's long duration matter for microdosing?
It is one of the features that distinguishes it from psilocybin descriptively. At perceptual doses LSD lasts far longer, and its pharmacokinetics show a prolonged plasma course. [2] Peer-reviewed Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects doi:10.1007/s40262-017-0513-9 People often cite this as a reason psilocybin is more commonly chosen, but that is a practical observation, not a recommendation. This cluster does not advise which substance to use or how to schedule anything; duration is reported here only as part of describing what LSD is.
Is LSD microdosing evidence stronger than psilocybin evidence?
It is different, not simply stronger. LSD has direct placebo-controlled microdosing studies, including self-blinding work, [3] Clinical trial Self-blinding citizen science to explore psychedelic microdosing doi:10.7554/eLife.62878 while psilocybin is the most represented substance in surveys and the few trials. But neither evidence base establishes broad, reliable benefits beyond expectation, and the two are not interchangeable: LSD and psilocybin differ in chemistry, duration, dose scale, and study design. [1] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 “Better studied” in one respect does not mean recommended, and evidence from one should not be treated as evidence for the other.